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Abstract 
 The European Union has achieved near-universal health coverage (Mean=99.15%; 
Standard Deviation=1.46%; Variation Coefficient=1%) and equity of access to healthcare 
services but, in the period 2000-10, such goal has been achieved at a Not Sustainable rate with 
total health expenditure growth (4.2%, STDDEV=2.4%) exceeding the growth rate of the 
GDP (1.7%,STDDEV=1.4%) by +2.5 percentage points on average and pharmaceutical 
expenditure (3.5%, STDDEV=3.0%) exceeding the growth rate of the GDP by +1.8 points.  
In the period 2011-2060 the GDP is expected to reduce and stabilize its growth rate from an 
average of 1.7% (STDDEV=1.4%) to an average of 1.6% with lower variation among the 
countries of the EU (STDDEV=0.5%). There follows that if the growth rate of health and 
pharmaceutical expenditure of the period 2000-10 is not reduced in the period 2011-60 only 4 
nations will achieve economic and financial sustainability: Netherlands, Sweden, Denmark 
and Italy. Health policymakers in the European Union should account for this long-term 
expenditure growth pattern and reform in the efficiency and effectiveness of health and 
pharmaceutical care is necessary if health outcomes are to be improved and at the same time 
the economic and financial sustainability of the European universal welfare model is to be 
preserved and inequality avoided.  
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Background 
The member states of the European Union guarantee near-universal health coverage 
(Mean=99.15%; Standard Deviation=1.46%; Variation Coefficient=1%) [43][45] and equity 
of access to healthcare services and pharmaceutical active principles approved by the 
European Medicines Agency and national Agencies for reimbursement [6][15].  However in 
2013 [44] the enduring effects of the 2008 financial crisis, in terms of recession, growing 
sovereign debt [1] and Financial consolidation [46], have risen concerns [44] about the long-
term [42][44] sustainability [49] of the European welfare model.  
The research question of this paper is whether the Per Capita Real Average Annual 
Growth Rate (PCR-AAGR) of pharmaceutical expenditure in the European Union in the 
period 2000-2010 (PCR-AAGR=3.5%; STDDEV=3.0%; VC=0.9) will be economically and 
financially sustainable in the long-term, i.e. in the period 2011-2060, on the basis of the 
OECD estimate of the growth of the Gross Domestic Product in such period of (PCR-
AAGR=1.6%; STDDEV=0.5%; VC=0.3) (Exhibit 1). 
In order to assess systematically across the EU the joint economic and financial 
sustainability of pharmaceutical expenditure in the periods 2000-10 and 2011-60, the present 
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paper has applied the World Health Organization’s conceptual framework outlined by 
Thomson, S., Foubister T. and Mossialos E. (WHO 2009). 
Exhibit 1: Per Capita Real Average Annual Growth Rate of GDP, Total Health Expenditure and Total 
Pharmaceutical Expenditure in the European Union (N=21) in the periods 2000-2010 and 2011-2060 
EU 21 GDP 2000-2009 
THE 
2000-2010 
TPE 
2000-2010 
GDP 
2011-2060 
Mean 1.7 4.2 3.5 1.6 
Standard Deviation 1.4 2.4 3.0 0.5 
Variation Coefficient 0.8 0.6 0.9 0.3 
Source:  Authors’ elaborations on OECD Health Data 2011 
 
Legenda: 
PCR AAGR – Per Capita Real Average Annual Growth Rate 
GDP – Per Capita Real Gross Domestic Product; 
THE – Per Capita Real Total Healthcare Expenditure 
TPE - Per Capita Real Total Pharmaceutical Expenditure 
 
Methods 
Thomson S., Foubister T., and Mossialos E. (WHO 2009) [53] define economic and 
Financial sustainability as:  
• Economic sustainability specifically refers to growth in public health financing 
as a proportion of gross domestic product (GDP). Financing on health is 
sustainable up to the point at which the social cost of health financing exceeds the 
value produced by that financing. If health financing sufficiently threatens other 
valued areas of economic activity, health financing may come to be seen as 
economically unsustainable. In order to exemplify, every dollar spent on health 
care represents one fewer dollars spent on education, national defense, housing, 
subsidies. The more we spend on health care, the less we are able to spend 
elsewhere;  
• Financial sustainability of a health system relates specifically to public 
financing on health care. A health care system may be economically sustainable 
and yet Financially unsustainable if internal public revenue is not sufficient to 
meet public financing.  
In the present research we will adapt the WHO definition of Financial and economic 
sustainability in a such a way that pharmaceutical expenditure, as any other expenditure, in 
order to be sustainable must be first of all financially and then economically sustainable.  In 
other words, if a category of expenditure is not financially sustainable, its economic 
sustainability cannot be assessed since Financial consolidation and pervasive reform make 
predictions regarding the direction of economic restructuring unreliable.  
In conditional terms, if: 
• PCR-AAGR is the per capita real annual average growth rate; 
• GDP the gross domestic product; 
• THE is total healthcare expenditure and; 
• TPE is total pharmaceutical expenditure: 
then pharmaceutical expenditure of a health system is: 
• Financially Sustainable   =if PCR-AAGR TPE ≤  PCR-AAGR GDP{ } and Not 
Sustainable otherwise; 
•  Economically Sustainable   =if PCR-AAGR TPE ≤  PCR-AAGR GDP{ }and PCR-AAGR TPE ≤  PCR-AAGR THE{ } and 
Financially Sustainable otherwise. 
This approach is synthesized in Exhibit 2. The red line represents f(x)=1 along which per 
capita real average annual growth rate of the GDP (x axis) is equal to the growth rate of total 
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health and pharmaceutical expenditure (y axis). The reduction in variability in the growth rate 
of the GDP across the EU in the period 2011-60 can be seen in terms of the clustering of 
datapoints around the mean.  The effects of this variation of the GDP growth rate in terms of 
the divergence of the regression lines of total health and pharmaceutical expenditure can also 
be visualized together with the reduction in the values of the  coefficients of determination 
(R2) from 2000-10 to 2011-60 of both health expenditure (from 0.66 to 0.31) and  
pharmaceutical expenditure (from 0.44 to 0.66).  
This paper analyzes the OECD healthcare and pharmaceutical expenditure and 
reimbursement datasets for the period 2000-2009 and the OECD report on long-term 
economic growth in the period 2011-2060. 
For definitions and comparability we refer in full to the: “OECD, Eurostat, World Health 
Organization: A system of health accounts – Edition 2011”. The OECD defines 
pharmaceutical expenditure as:  
Pharmaceutical expenditure covers spending on prescription medicines and self-
medication, often referred to as over-the-counter products. For some countries, other medical 
non-durables such as syringes, bandages, etc. may be included in the total. It also includes 
pharmacists’ remuneration when the latter is separate from the price of medicines. 
Pharmaceuticals consumed in hospitals are excluded (on average they account for around 
15% of total pharmaceutical spending). Final expenditure on pharmaceuticals includes 
wholesale and retail margins and value-added tax. 
The 21 countries of the European Union analyzed have been selected on unbiased 
grounds as the only countries for which all information was available and homogeneous in the 
OECD databases. 
Per capita real data have been utilized to account for the demographic dividend and 
inflation. 
All data has been downloaded in .csv formats and analyzed-plotted with R 3.0.1 software. 
Exhibit 2: Per Capita Real Average Annual Growth Rate of the Gross Domestic Product, of Total 
Healthcare Expenditure and of Total Pharmaceutical Expenditure in 21 member states of the European 
Union in the period 2000-10 and 2011-60 
 
Source:  Authors’ elaborations on OECD Health Data 2011 
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Legenda: 
BLACK DOTS - Per capita real Average Annual Growth Rate of Pharmaceutical Expenditure (TPE) 
HOLLOW DOTS - Per capita real Average Annual Growth Rate of Total Health Expenditure (THE) 
SOLID LINE – Regression Line of TPE 
DASHED LINE – Regression Line of THE 
RED LINE – f(x)=1 
Notes: 
Countries in decreasing order of AAGR GDP. EU N=21 out of N=27 member states have been analyzed 
for which the OECD datasets are consistent in the period 2000-2010 and 2011-2060 The original misalignment 
in the OECD datasets between the time period 2000-2009 of GDP growth and the time period 2000-2010 of 
Total Healthcare and Pharmaceutical Expenditure has been maintained for consistency with the OECD Health 
Data 2011 datasets. 
 
Findings 
From an economic and financial point of view Exhibits 1 and 2 highlight the fact that, 
in the post-Euro currency period 2000-2010, in 21 member states of the European Union (EU 
21) the per capita real Average Annual Growth Rate (PCR-AAGR) of Total Healthcare 
Expenditure (PCR-AAGR=4.2%; STDDEV=2.4%; VC=0.6) has been consistently higher 
than the PCR-AAGR of the national Gross Domestic Product (PCR-AAGR=1.7%; 
STDDEV=1.4%; VC=0.8), with the sole exception of Luxembourg. One country, Italy, 
highlights a positive growth of Total Healthcare Expenditure (PCR-AAGR=1.6%) even if the 
growth of the GDP is negative in the same period (PCR-AAGR=-0.2%).  
As far as Pharmaceutical Expenditure is concerned, the situation is only slightly 
different (PCR-AAGR=3.5%; STDDEV=3.0%; VC=0.9), with only 2 members for whom the 
growth rate is lower than the growth rate of the GDP - Poland (PCR-AAGR=3.4%) and 
Slovenia (PCR-AAGR=1.9%) - and 2 for whom it is actually negative: Luxembourg (PCR-
AAGR=-0.8%) and Italy (PCR-AAGR=-0.5%). 
Exhibit 3 analyzes the difference between the growth rate of pharmaceutical 
expenditure and GDP (Financial Sustainability) in the two periods 2000-10 and 2011-60. In 
the long-term the difference in the EU 21 will be less uniformly distributed with a mean of 
1.9% (STDDEV=2.8%) against the 1.7% (STDDEV=2.3%) of the period 2000-2009 and, as 
the OECD points out  [32], only in the presence of ambitious policy changes, ambitious 
Financial consolidation efforts and deep structural reforms. 
Exhibit 3: Financial Sustainability of Pharmaceutical Expenditure in the European Union (N=21) in the 
periods 2000-2010 and 2011-2060 
 
Source:  Authors’ elaborations on OECD Health Data 2011 
Legenda: 
PCR AAGR – Average Annual Growth Rate 
Notes: 
Software R 3.0.1 – boxplot() 
European Scientific Journal   December 2013 /SPECIAL/ edition vol.1 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
492 
 
Conclusions 
In the period 2000-10 all the 21 countries of the European Union analyzed have 
achieved near-universal health coverage (Mean=99.15%; Standard Deviation=1.46%; 
Variation Coefficient=1%) [43][45] and equity of access to healthcare services [6][15] but 
such goal has been achieved at a Not Sustainable rate (Exhibit 2), with total health 
expenditure  growth (4.2%) exceeding the growth rate of the GDP (1.7%) by +2.5 percentage 
points on average and pharmaceutical expenditure (3.5%) exceeding the growth rate of the 
GDP by +1.8 points. Only 4 countries out of 21 have grown at a sustainable rate: 
Luxembourg, Slovenia, Italy and Poland. 
In the period 2011-2060, in the 21 countries analyzed, the GDP is expected to reduce 
and stabilize its growth rate from an average of 1.7% (STDDEV=1.4%) to an average of 1.6% 
(STDDEV=0.5%): -0.1% (STDDEV=1.5%). More specifically, if the growth rate in 
healthcare and pharmaceutical expenditure of the period 2000-10 is not modified in the period 
2011-60, only 4 nations will achieve economic and financial sustainability: Netherlands, 
Sweden, Denmark and Italy. 
Exhibit 4 summarizes all conclusions: form a quasi-normal distribution in the period 
2000-10 in the period 2011-60 the reduction in the variation of the real per capita GDP 
growth rate in the EU will for some countries skew the distribution of the difference between 
the growth rate of pharmaceutical expenditure and  GDP (Financial Sustainability) to the left, 
making it more financially sustainable but, on the other hand, for some other countries, the 
reduction in the growth rate of the GDP will render pharmaceutical expenditure less 
financially sustainable in the long-term and skew their distribution to the right. 
Exhibit 4: Normal Quantile-Quantile Plot (Z standardized variables) of the Financial Sustainability of 
Pharmaceutical Expenditure in the European Union (N=21) in the period 2000-2010 and 2011-2060 
 
Source:  Authors’ elaborations on OECD Health Data 2011 
Legenda: 
AAGR – Average Annual Growth Rate 
Notes: 
Software R 3.0.1 – qqnorm() 
 
We conclude that health policymakers in the European Union should account for this 
long-term expenditure growth patterns, and reform in the efficiency and effectiveness of 
health and pharmaceutical care is necessary if health outcomes are to be improved and at the 
same time the economic and financial sustainability of the European universal welfare model 
is to be preserved and inequality avoided. 
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